Niagen Bioscience, Inc. NAGE
3.05
0.04
1.33%
as of 25 Sep
- Market cap
- $238.2M
- P/E
- 15.2×
Follow NAGE
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 21.80% | 27.07% | 28.35% | 38.90% |
+8 more TTM periods Free account |
|
| 16.14% | 19.05% | 19.90% | 26.42% | ||
ROIC |
41.95% | 51.81% | 86.63% | 188.93% | |
Return on Tangible Assets |
19.04% | 22.29% | 22.22% | 28.22% | |
Average Days of Receivables |
24.26 | 36.57 | 27.47 | 24.90 | |
Free Cash Flow per Share |
0.14 | 0.12 | 0.17 | 0.27 | |
Free Cash Flow |
11.47 | 9.91 | 13.21 | 21.15 | |
Capital Expenditures |
5.53 | 5.48 | (0.29) | (0.26) | |
Piotroski F-Score |
4.00 | 4.00 | 5.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
3.99% | 2.97% | 9.56% | 15.86% | |
Accounts Receivable Turnover |
14.16 | 12.96 | 14.78 | 15.99 | |
Accounts Payable Turnover |
3.99 | 3.90 | 4.79 | 4.58 | |
Inventory Turnover |
2.63 | 2.65 | 3.12 | 3.07 | |
Average Days of Payables |
74.63 | 104.03 | 85.23 | 103.29 | |
Days of Inventory on Hand |
163.20 | 188.18 | 161.24 | 152.32 | |
Tax Rate |
(0.06) | (0.05) | (0.04) | (0.02) | |
Research and Development Expense of Revenue |
5.03% | 5.02% | 4.89% | 4.76% | |
Selling, General and Administrative Expense of Revenue |
52.53% | 50.75% | 48.34% | 43.66% | |
Share Based Compensation of Revenue |
5.38% | 5.14% | 4.69% | 4.07% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.37 | 0.24 | 0.78 | 1.05 | |
Depreciation/Fixed assets |
0.78 | 0.68 | 0.59 | 0.52 | |
Capex/Depreciation |
5.66 | 6.22 | (0.37) | (0.34) | |
Revenue per Share |
1.63 | 1.63 | 1.63 | 1.56 | |
Operating CF per Share |
0.08 | 0.06 | 0.17 | 0.27 | |
Capex per Share |
0.07 | 0.07 | 0.00 | 0.00 | |
Capex to Sales |
(0.04) | (0.04) | 0.00 | 0.00 | |
Net Profit Margin |
12.39% | 14.29% | 13.43% | 16.38% |
Columns are period end dates